Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hepatocellular carcinoma
(
HCC
) is a malignant tumor with high incidence and high risk. Study of the role and mechanism of miRNAs are a hot spot of research providing new treatment ideas in malignant tumors. The effect of miR-642a on
HCC
progression and the underlying molecular mechanism were investigated. Expression of miR-642a and
SEMA4C
was measured by western blot analysis and RT-PCR. miR-642a expression was elevated while
SEMA4C
expression was attenuated in
HCC
tissues and cells. Results of luciferase reporter and western blot analyses show that miR-642a modulated
SEMA4C
expression by binding to its 3'UTR. Moreover, miR-642a negatively regulated
SEMA4C
expression.
HCC
cell migration and invasion was tested by Transwell assays. The findings revealed that the number of migrated and invaded cells were reduced by miR-642a mimic and raised by miR-642a inhibitor, indicating that miR-642a showed a suppression effect on
HCC
cell migration and invasion. Additionally, the migration and invasion of
HCC
cells were inhibited by
SEMA4C
siRNA, and
SEMA4C
reversed miR-642a effect on
HCC
migration and invasion. Furthermore, p38 MAPK signaling pathway was proven to be inhibited by miR-642a mimic, whereas facilitated by miR-642a inhibitor and
SEMA4C
siRNA could overturn the promotion effect of miR-642a inhibitor. Briefly, miR-642a targeted
SEMA4C
to repress
HCC
cell migration and invasion through p38 MAPK signaling pathway providing a new strategy for treatment of
HCC
patients.
...
PMID:miR-642 serves as a tumor suppressor in hepatocellular carcinoma by regulating SEMA4C and p38 MAPK signaling pathway. 3286 7